Everads Therapy
Delivery System for Injectable Therapies into the Eye
Company Overview
Snapshot
Founded in January 2017 by Dr. Ifat Sher, Dr. Ygal Rotenstreich, and David Daily, Everads Therapy is an early-stage life sciences company with 1–10 employees. The company has secured $1 million in total capital across one funding round from two investors. In May 2026, Everads Therapy announced the publication of its first-in-human clinical data for its suprachoroidal injector in Ophthalmology Science.
Business overview
Everads Therapy is a Health Tech & Life Sciences company focused on developing retinal treatment delivery technologies. The company's core product is a delivery system designed to enhance the efficacy and safety of existing and new drug therapies for retinal and macular diseases. Operating within the Medical Devices, Medical Treatment & Therapeutics, Pharma & Medical Biotechnology, and Drug Delivery sectors, Everads Therapy aims to address significant challenges in current treatment methodologies for eye conditions, serving the healthcare and life sciences markets globally.
Strategic signal
In May 2026, Everads Therapy announced the publication of its first-in-human clinical data for its suprachoroidal injector in. This publication and presentation activity signals significant progress in validating their novel suprachoroidal delivery technology, demonstrating clinical advancement and scientific recognition that could attract further investment and partnerships in the ophthalmic drug delivery market.
Log in to access full profile ›Company Intelligence Q&A
- What is Everads Therapy's primary focus?
- Everads Therapy is focused on developing retinal treatment delivery technologies to improve the efficacy and safety of injectable therapies for eye diseases.
- When was Everads Therapy founded?
- Everads Therapy was founded in January 2017.
- What was a key clinical milestone for Everads Therapy in May 2026?
- In May 2026, Everads Therapy announced the publication of its first-in-human clinical data for its suprachoroidal injector in Ophthalmology Science, along with three presentations at ARVO 2026.
- What was a significant commercial development for Everads Therapy in August 2020?
- In August 2020, a global pharma company exercised its rights for the exclusive use of Everads Therapy's drug delivery technology in specific retinal targets.
- What was a notable collaboration for Everads Therapy in June 2021?
- In June 2021, Everads Therapy entered into a collaboration to evaluate its suprachoroidal delivery technology with a clinical-stage gene therapy company.